Biogen Inc
NASDAQ: BIIB
$142.54
+$1.56 (+1.1%)
Real Time Data Delayed 15 Min.
BIIB Articles
Biogen reported better than expected third-quarter financial results with disappointing guidance before the markets opened on Wednesday.
Published:
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
The August 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
The world may be focused on COVID-19 this year, but the battle against Alzheimer’s disease continues with no effective treatments. Biogen hopes to remedy that unfortunate situation.
Published:
Denali Therapeutics announced early Thursday that it would be progressing its Parkinson’s treatment into late-stage studies in collaboration with Biogen.
Published:
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Monday's top analyst upgrades and downgrades included Albermarle, Biogen, Dun & Bradstreet, eBay, First Solar, Lemonade, Morgan Stanley, Procter & Gamble, Schlumberger and Verizon Communications.
Published:
24/7 Wall St. looks at some potential winners among Warren Buffett’s holdings. See why they could rally headed toward 2021 and beyond.
Published:
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Biogen may be on track to be one of the first companies with a meaningful treatment for Alzheimer’s disease, and this could have huge implications for the stock.
Published:
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.